Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733002 | 0.90 | MGLL (0.40) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL26240876 | 0.88 | MGLL (0.39) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL24841890 | 0.86 | MGLL (0.52) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL27281798 | 0.86 | MGLL (0.52) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL27281807 | 0.86 | MGLL (0.52) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL27281819 | 0.82 | MGLL (0.56) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL27283086 | 0.79 | MGLL (0.53) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL22856397 | 0.79 | MGLL (0.56) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL26240870 | 0.79 | MGLL (0.53) | MGLLPIK3CDCYP2D6SMN1; SMN2TSHR | |
| SCHEMBL22853942 | 0.77 | MGLL (0.35) | MGLLPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | HSF1, HSP90AB1, HSP90AB2P | MGLL 4797/4885PIK3CD 1262/4885CYP2D6 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.